TELA Bio (TELA) Gains from Investment Securities (2018 - 2019)

TELA Bio's (TELA) quarterly Gains from Investment Securities came in at $1000.0 in Q4 2019, up 101.89% year-on-year from $495.33 in Q4 2018, and up 102.94% quarter-over-quarter from -$34000.0 in Q3 2019.

TELA Bio (TELA) Gains from Investment Securities (2018 - 2019) Analysis & Trends

TELA Bio's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $1000.0 for Q4 2019.

  • On a quarterly basis, Gains from Investment Securities rose 101.89% year-over-year to $1000.0 in Q4 2019; TTM through Dec 2022 was -$33000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $888000.0, changed 0.11% from the prior year.
  • Gains from Investment Securities climbed to $1000.0 in Q4 2019 per TELA's latest filing, from -$34000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $74000.0 in Q2 2019 and bottomed at -$53000.0 in Q4 2018.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn
8 Smith & Nephew 26.99 Bn 26.41 Bn -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn
10 TELA Bio 38.36 Mn -1.18 Mn 12.52 Mn

Historic Data

Download Data
DateValue
Dec 31, 2019 1,000.00
Dec 31, 2019 1,000.00
Sep 30, 2019 -34,000.00
Sep 30, 2019 -34,000.00
Jun 30, 2019 74,000.00
Jun 30, 2019 74,000.00
Mar 31, 2019 -36,000.00
Mar 31, 2019 -36,000.00
Dec 31, 2018 -53,000.00
Dec 31, 2018 -53,000.00
Sep 30, 2018 -17,000.00
Sep 30, 2018 -17,000.00